The susceptibility of uremic patients to infectious disease has been widely reported, but the host immune factors associated with the increased incidence of infection have not been clearly defined. In this study, the possibility of synergism between biologically active components that accumulate in uremia and immunosuppressive drugs used in the course of management was investigated. An animal model of chronic stable uremia was used in these experiments to assess the effect of cyclophosphamide, methotrexate, and azathioprine on antibody response in the uremic host. Chronic uremia did not affect the immunosuppressive activity of cyclophosphamide, methotrexate, or azathioprine, and synergism between these agents and uremic components is unlikely to complicate further the immune status of the host in renal failure.
The effect of uremia on host immune responses has been examined in an earlier series of experiments (5, 7, 11 ; J. Nelson, D. J. Omrod, and T. E. Miller, Kidney Int., in press). These studies have shown that no single component of the cellular immune mechanism is compromised to a degree that could account for the increased incidence of infectious disease found in uremic patients. Thus, there is a disparity between ekperimental findings and clinical observations. One explanation is that drugs commonly used in the management of renal failure become immunomodulatory in the uremic host. Immunosuppressive drugs are frequently given to patients in renal failure, and in a case report it was postulated that synergism between these agents and biologically active components that accumulate in uremia might lead to an increased susceptibility to infection (4) . Others have stated that such a combination predisposes patients to serious infection (3, 6, 9, 10), but to date no experimental evidence for or against this postulate has been presented. A model of chronic stable uremia has been developed recently in our laboratory (8) . In the present experiments, this carefully defined model was used to evaluate the combined effect of uremia and the administration of the immunosuppressive drugs cyclophosphamide, methotrexate, and azathioprine on the antibody response to sheep erythrocytes (SRBC (Fig. 1) antibody response in normal and uremic animals.
Azathioprine in uremia. A similar protocol was followed with control and uremic animals treated with azathioprine. Administration of the drug reduced both the primary and secondary immune response to SRBC to 50% of the response found in untreated animals (Fig. 3) . Uremia did not increase the degree of depression of immune responsiveness by azathioprine.
DISCUSSION
The immune status in uremia is difficult to assess in patients subjected to stress, surgical procedures, multiple drug therapy, and rapid changes in renal function. It can be said, therefore, that in many clinical studies the immune status of a compromised host, rather than the influence of uremia on immune mechanisms, has been evaluated. These problems can be overcome by studying immune mechanisms in a clearly defined animal model of chronic uremia free from the therapeutic variables associated with patient management.
In a series of related experiments utilizing this model, cell-mediated immune mechanisms, antibody responses, neutrophil function, and reticuloendothelial function were examined and shown to be normal despite chronic uremia (5, 7, 11; Nelson et al., in press). Nonetheless, an increased incidence of infection in patients with renal failure has been reported (6, 12) . Many incidents of infection can be attributed to manipulations affecting host resistance. These include surgical manipulations, catheterization, damage to the mucous membranes, and poor drainage of secretions. Uremia, however, has been shown to be associated with a significant increase in the incidence of infection in immunosuppressed individuals (3), but the effect of individual factors on immune status was not determined. Our thesis was that, even if uremia alone could not explain the increased susceptibility of the host to infection, immune mechanisms might be suppressed as a result of an interaction between a factor associated with uremia and immunosuppressive drugs used in patient management. Many substances found in vivo, such as the corticosteroids, the prostaglandins, certain a globulins, and fibrin degradation products, have immunosuppressive effects, and the possibility that some of these substances might act synergistically with administered immunosuppressive agents to enhance the degree of immunosuppression needed evaluation.
In the first instance, we examined the combined effect of uremia and each of the three immunosuppressive drugs cyclophosphamide, methotrexate, and azathioprine. A protocol was devised whereby the drugs were given in doses that significantly reduced but did not abrogate the immune response. This allowed any synergism between uremia and immunosuppressive agents to be readily assessed. The results confirmed previous findings that uremia per se did not affect the ability of the host to respond to an antigenic challenge (7) . In addition, it was established that the administration of immunosuppressive agents depressed the immune response as anticipated, but the degree of suppression was not enhanced in animals with chronic uremia. One anticipated criticism of the protocol used in these experiments is that the immunosuppressive agents were administered as a "pulse" rather than on a regular basis, as would be the case in clinical practice. Drug accumulation after chronic administration, however, presents a major obstacle to the interpretation of the results of such an experiment, and a protocol during which the minimum dose capable of reducing the immune responsiveness of the host by 50% was selected as the most appropriate regimen. Under these conditions, drug accumulation was reduced to a minimum so that any observed effects of uremia on the activity of the immunosuppressive agents could be ascribed to synergism rather than drug accumulation. Although there does not appear to be any synergism between uremic components and immunosuppressive agents in relation to antigenic responsiveness, an effect on other facets of the immune response cannot be ruled out. We are currently developing several models of infectious disease to resolve this problem. 
